Capital Asset Advisory Services LLC Reduces Stake in AstraZeneca PLC (NASDAQ:AZN)

Capital Asset Advisory Services LLC cut its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 7.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,960 shares of the company’s stock after selling 378 shares during the period. Capital Asset Advisory Services LLC’s holdings in AstraZeneca were worth $335,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in AZN. 180 Wealth Advisors LLC lifted its holdings in AstraZeneca by 4.6% during the 1st quarter. 180 Wealth Advisors LLC now owns 8,291 shares of the company’s stock valued at $562,000 after buying an additional 368 shares in the last quarter. Thrive Wealth Management LLC raised its stake in shares of AstraZeneca by 5.0% during the first quarter. Thrive Wealth Management LLC now owns 4,020 shares of the company’s stock valued at $272,000 after acquiring an additional 192 shares in the last quarter. Tlwm purchased a new stake in shares of AstraZeneca in the first quarter valued at approximately $1,091,000. Wealth Enhancement Advisory Services LLC grew its stake in AstraZeneca by 57.3% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 181,601 shares of the company’s stock worth $12,303,000 after purchasing an additional 66,181 shares in the last quarter. Finally, Procyon Advisors LLC increased its holdings in AstraZeneca by 16.3% during the 1st quarter. Procyon Advisors LLC now owns 24,550 shares of the company’s stock worth $1,663,000 after purchasing an additional 3,438 shares during the period. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Barclays raised AstraZeneca to a “strong-buy” rating in a research report on Monday. Citigroup upgraded shares of AstraZeneca to a “strong-buy” rating in a report on Monday. BMO Capital Markets boosted their price objective on shares of AstraZeneca from $80.00 to $82.00 and gave the stock an “outperform” rating in a research note on Friday, April 26th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, April 16th. Finally, Argus upped their price target on shares of AstraZeneca from $80.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday, May 30th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $88.00.

AstraZeneca Stock Performance

NASDAQ:AZN traded down $0.19 during mid-day trading on Friday, hitting $77.99. The company’s stock had a trading volume of 3,627,332 shares, compared to its average volume of 5,592,171. The business’s fifty day moving average is $77.33 and its two-hundred day moving average is $70.25. The stock has a market cap of $241.81 billion, a price-to-earnings ratio of 38.32, a PEG ratio of 1.42 and a beta of 0.48. The company has a debt-to-equity ratio of 0.73, a current ratio of 0.89 and a quick ratio of 0.70. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $80.86.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Thursday, April 25th. The company reported $1.03 EPS for the quarter, topping the consensus estimate of $0.95 by $0.08. AstraZeneca had a return on equity of 30.42% and a net margin of 13.30%. The firm had revenue of $12.68 billion for the quarter, compared to analyst estimates of $11.92 billion. Analysts anticipate that AstraZeneca PLC will post 4.04 EPS for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.